Davut Ibrahim Mahcicek1, Dursun Korel Yildirim1, Gokce Kasaci1, and Ozgur Kocaturk1
1Biomedical Engineering, Bogazici University, Istanbul, Turkey
Synopsis
In this study, a novel MRI guided prostate biopsy device was designed,
produced and tested under MRI. In this scope, a MRI compatible, remote controlled,
transrectal biopsy delivery system, a MRI compatible biopsy gun, a MRI
compatible, biopsy needle which can be tracked under MRI, and a computer based
control unit were designed and a prototype was produced. The robotic prostate
biopsy device prototype was tested under MRI with in-vitro experiments using a
commercially available prostate phantom.
Introduction
The prostate cancer (PCa) is the one of the most
frequently diagnosed cancer type in men with very high mortality rate
1.
In clinical routine, PCa diagnosis is performed with transrectal ultrasound (TRUS)
imaging guided biopsy operation. Although, TRUS biopsy is the current golden
standard for prostate biopsy %20 false-negative result were reported
2
because 40% of the PCa lesions were reported to be iso-echoic under ultrasound
imaging
3. With this project we aim to
address current diagnostic issues of PCa and eventually provide much reliable
diagnostic tool for PCa. The main purpose is performing whole prostate biopsy
procedure under MRI which provides better visualization of PCa lesions. Due to
the technical limitations of working under MRI we developed a novel MRI compatible,
remote controlled robotic biopsy delivery system and MRI visible biopsy tools
to perform prostate biopsy.
Methods
Performing any clinical procedure under MRI requires special tools or devices due to the nature of MRI. The robotic
prostate biopsy device was designed to cope with the complexities and
limitations of working under MRI. Initially, anatomically compliant robotic
biopsy delivery device was designed (figure 1). In this design, three degrees
of freem (DoF) remote control and three DoF manual control was included.
The manual controls were used to position the biopsy delivery system and remote
controls were used to target and reach the cancer lesions inside the prostate.
Besides, the distal end of the biopsy delivery system was designed to have
equidistantly placed MRI contrast agents in order to track the insertion of the
distal tube trans-rectally. By this means it was possible to track and locate
the biopsy delivery system inside the patient/phantom image. The biopsy
delivery system was produced from non-metallic, non-ferromagnetic materials in
order not to disturb the homogeneity of magnetic field and to prevent heating
due to RF power transmission.
The biopsy gun designed to fit onto the biopsy
delivery system. Similarly, MRI compatible materials were used to produce the
biopsy gun. Tight fit coaxial nitinol tubes were used to
produce inner (Confluent Medical Technologies, 0.0370 inch) and outer (Confluent Medical Technologies, 0.0580 inch) biopsy needles. Both nitinol tubes were shaped using a Nd:YAG laser cutting system in order to extract sufficient biopsy samples.
Nitinol tubes were also marked with iron-oxide (Fe2O3) strips using physical vapor deposition system in order to locate and measure the insertion depth of
the biopsy needle.The actuation of the remote controls on robotic biopsy
device was obtained using hydraulic cylinders. For each remote control one MRI
compatible hydraulic cylinder (slave) was placed on the robotic biopsy delivery
system and one hydraulic cylinder (master) was placed outside the MRI room. The
master and slave hydraulic cylinders were connected in series and the line was
loaded with 2 bar pressure. The master cylinder was controlled with a
Raspberry-Pi based motor control system (figure 2). The slave cylinder inversely
replicated the movement of the master cylinder. Results
The transrectal biopsy delivery system, biopsy gun,
biopsy needles and robotic remote control were tested under MRI using a
prostate phantom (CIRS, 053L). A 3T MRI scanner (Siemens Medical Systems) and
12ch head coil were used to image the prostate phantom and lesions inside the
prostate phantom.
The MRI compatibility of the robotic biopsy delivery
system was tested using a T2 weighed Turbo Spin Echo sequence (TR: 4000 ms, TE:
102 ms). The SNR loss due to introducing the biopsy delivery system was
measured as less than 3%. (figure 3)
In order to obtain 3D
images SPACE sequence (TR: 3000, TE: 424) was used to perform the biopsy
procedure. In three consecutive movements it was possible to get biopsy samples
from the lesion inside the prostate with 1 mm accuracy.Discussions
Performing prostate biopsy procedure under MRI with a remote control capability will help clinicians to diagnose PCa with better reliability in a better workflow compared to conventional TRUS biopsy which will eventually help to combat with PCa. Moreover, the study showed that other clinical procedures might leverage from image quality of MRI and might be performed under MRI with a similar robotic system.Conclusions
The robotic biopsy delivery system was designed and the feasibility of performing prostate biopsy procedure was validated using a commercial prostate
biopsy phantom under MRI. The robust and stable mechanical design of the hydraulic based robotic biopsy system enabled to reach target location with 1
mm accuracy. The real time MRI imaging during phantom studies also confirmed the MRI compatibility of both biopsy needle and assisted robotic system.
The tumor locations within the phantom were clearly visualized throughout the procedure without compromising the image quality.
Acknowledgements
This project is funded by Scientific and Technological Research Council of Turkey (TUBITAK) 1001 programme with project ID:115E271.References
1.
Torre LA, Bray F, Siegel RL, Ferlay, et al. Global Cancer Statistics.
CA Cancer Journal. 2012;65(2): 87-108.
2.
Rabbani
F, Stroumbakis N, Kava BR, et al. Incidence and Clinical Significance of False
Negative Sextant Prostate Biopsies. The Journal of Urology. 2004;159(4):1247-1250
3.
Presti
JC, Jr. O’Dowd GJ, Miller MC, et al. Extended Peripheral Zone Biopsy Schemes
Increase Cancer Detection Rates and Minimize Variance in Prostate Specific
Antigen and Age Related Cancer Rates: Results of a Community Multi-Practice
Study. The Journal of Urology. 2003;169: 125-129.